EPRX$7.20
Chart
Performance
Key Stats
AI EPRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldEupraxia Pharmaceuticals Inc. shows promising development in its clinical pipeline, supported by a strong balance sheet. However, the lack of revenue and ongoing operational losses, coupled with a high valuation for its stage, suggest a 'Hold' rating. The company's thematic alignment with unmet medical needs in inflammatory conditions is a key long-term positive.
Thematic
Eupraxia Pharmaceuticals is well-aligned with the thematic trend of addressing significant unmet medical needs in biotechnology, particularly in pain relief and inflammatory diseases. Its Diffusphere technology offers a unique delivery mechanism for various therapeutic applications.
Fundamental
Eupraxia Pharmaceuticals demonstrates a sound financial position with substantial cash reserves and manageable debt. However, it operates at a loss with no current revenue, making valuation metrics like P/E ratios inapplicable and growth dependent on future clinical success and commercialization.
Technical
Eupraxia Pharmaceuticals is trading within a 52-week range, showing some recent upward momentum but with mixed signals from oscillators. The stock is below key moving averages, suggesting a bearish short-term trend that could reverse with positive clinical news.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Unmet Medical Needs | 80 |
| Proprietary Technology | 80 |
| Market Growth Potential | 70 |
| Regulatory Environment | 60 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 85 |
| Cash Flow | 20 |
| Debt Level | 95 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume | 60 |
| Support & Resistance | 70 |
| Short-term Indicators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Post-Market Momentum
The post-market price is trading at $5.88, up 7.10% from the closing price, suggesting positive investor sentiment following the regular trading session.
Strong Short-to-Medium Term Performance
The stock has shown significant gains over multiple periods, including 74.95% in the last 6 months and 75.4% year-to-date, indicating strong recent investor interest and positive market reception.
Bearish Points (8)
Negative Earnings Per Share (EPS)
The EPS TTM (Trailing Twelve Months) is -0.76, and recent quarterly EPS estimates and reported figures are negative (e.g., -0.19 estimate vs. -0.21 reported for 2025 Q2), indicating the company is currently unprofitable on a per-share basis.
No Price-to-Sales (P/S) Ratio
The absence of a P/S ratio (0.0) across multiple valuation periods suggests the company has no reported revenue, which is a significant concern for a company seeking to generate value from its products.
Calendar
August 2025
8
Next Earnings Date
H: $-0.14
A: $-0.18
L: $-0.22
Profile
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Seasonals
Price Target
11.75 USD
The 39 analysts offering 1 year price forecasts for EPRX have a max estimate of 12.00 and a min estimate of 11.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Major tenant in EPR Properties' portfolio, representing a significant portion of their movie theater real estate holdings.
Weight: 98
Operator of ski resorts, which is a direct property type that EPR Properties invests in, aligning with their experiential real estate focus.
Weight: 95
Leading gaming and hospitality REIT, a direct competitor and peer in owning large-scale entertainment and leisure properties under net lease agreements.
Weight: 93
Prominent gaming REIT focused on casino and entertainment properties, operating with a similar triple-net lease structure to EPRX.